

# Diane C Bodurka

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/815175/diane-c-bodurka-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

146  
papers

8,723  
citations

46  
h-index

91  
g-index

150  
ext. papers

9,881  
ext. citations

3  
avg, IF

5.4  
L-index

#	Paper	IF	Citations
146	Pathologic distribution at the time of interval tumor reductive surgery informs personalized surgery for high-grade ovarian cancer. <i>International Journal of Gynecological Cancer</i> , <b>2021</b> , 31, 232-237	3.5	
145	Dasatinib, paclitaxel, and carboplatin in women with advanced-stage or recurrent endometrial cancer: A pilot clinical and translational study. <i>Gynecologic Oncology</i> , <b>2021</b> , 161, 104-112	4.9	2
144	An Integrated Approach to Selecting a Prepared Medical Decision-Maker. <i>Journal of Pain and Symptom Management</i> , <b>2021</b> , 61, 1305-1310	4.8	0
143	Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. <i>American Journal of Obstetrics and Gynecology</i> , <b>2021</b> , 224, 191.e1-191.e15	6.4	27
142	Long-term survival among 5-year survivors of adolescent and young adult cancer. <i>Cancer</i> , <b>2020</b> , 126, 3708-3718	6.4	13
141	Phase Ib/II study of weekly topotecan and daily gefitinib in patients with platinum resistant ovarian, peritoneal, or fallopian tube cancer. <i>International Journal of Gynecological Cancer</i> , <b>2020</b> , 30, 1768-1774	3.5	0
140	A Not So Perfect Score: Factors Associated with the Rate of Straight Line Scoring in Oncology Training Programs. <i>Journal of Cancer Education</i> , <b>2020</b> , 1	1.8	
139	Choosing Wisely: Decreasing the incidence of perioperative blood transfusions in gynecologic oncology. <i>Gynecologic Oncology</i> , <b>2019</b> , 153, 597-603	4.9	6
138	Women's preferences for cancer risk management strategies in Lynch syndrome. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 514-521	4.9	6
137	How we use hospice: Hospice enrollment patterns and costs in elderly ovarian cancer patients. <i>Gynecologic Oncology</i> , <b>2019</b> , 152, 452-458	4.9	1
136	Systematic Approach to Selecting and Preparing a Medical Power of Attorney in the Gynecologic Oncology Center. <i>Journal of Oncology Practice</i> , <b>2019</b> , 15, e1092-e1097	3.1	1
135	Prospective assessment of patient-reported outcomes in gynecologic cancer patients before and after pelvic exenteration. <i>Gynecologic Oncology</i> , <b>2018</b> , 149, 484-490	4.9	9
134	Gynecologic cancer survivor preferences for long-term surveillance. <i>BMC Cancer</i> , <b>2018</b> , 18, 375	4.8	9
133	Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study. <i>Gynecologic Oncology</i> , <b>2018</b> , 151, 18-23	4.9	13
132	Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device. <i>Obstetrics and Gynecology</i> , <b>2018</b> , 131, 109-116	4.9	87
131	Handoff Tool Enabling Standardized Transitions Between the Emergency Department and the Hospitalist Inpatient Service at a Major Cancer Center. <i>American Journal of Medical Quality</i> , <b>2018</b> , 33, 629-636	1.1	6
130	Defining the impact of the use of granulocyte colony stimulating factors on the incidence of chemotherapy-induced neutropenia in patients with gynecologic malignancies. <i>Journal of Oncology Pharmacy Practice</i> , <b>2017</b> , 23, 121-127	1.7	2

129	Hormonal Maintenance Therapy for Women With Low-Grade Serous Cancer of the Ovary or Peritoneum. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1103-1111	2.2	118
128	Nothing left to chance? The impact of locus of control on physical and mental quality of life in terminal cancer patients. <i>Supportive Care in Cancer</i> , <b>2017</b> , 25, 1985-1991	3.9	13
127	Comparison of four brief depression screening instruments in ovarian cancer patients: Diagnostic accuracy using traditional versus alternative cutpoints. <i>Gynecologic Oncology</i> , <b>2017</b> , 145, 562-568	4.9	6
126	Implementation of a standardized electronic tool improves compliance, accuracy, and efficiency of trainee-to-trainee patient care handoffs after complex general surgical oncology procedures. <i>Surgery</i> , <b>2017</b> , 161, 869-875	3.6	10
125	Factors influencing fertility-sparing treatment for gynecologic malignancies: A survey of Society of Gynecologic Oncology members. <i>Gynecologic Oncology</i> , <b>2017</b> , 147, 497-502	4.9	8
124	End-of-Life Racial and Ethnic Disparities Among Patients With Ovarian Cancer. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 1829-1835	2.2	26
123	The Advance Care Planning Readiness Scale: Development and Validation of a Measure of Willingness to Discuss and Acceptance of End-of-Life Care in Gynecologic Cancer Patients. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 838-846	3.5	3
122	Treatment Patterns, Outcomes, and Costs for Bowel Obstruction in Ovarian Cancer. <i>International Journal of Gynecological Cancer</i> , <b>2017</b> , 27, 1350-1359	3.5	9
121	The DISINFECT Initiative: Decreasing the Incidence of Surgical INFECTIONS in Gynecologic Oncology. <i>Annals of Surgical Oncology</i> , <b>2017</b> , 24, 362-368	3.1	21
120	Room for improvement: An examination of advance care planning documentation among gynecologic oncology patients. <i>Gynecologic Oncology</i> , <b>2016</b> , 142, 525-30	4.9	11
119	Dying well: How equal is end of life care among gynecologic oncology patients?. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 295-300	4.9	17
118	Fighting cancer together: Development and implementation of shared medical appointments to standardize and improve chemotherapy education. <i>Gynecologic Oncology</i> , <b>2016</b> , 140, 114-9	4.9	11
117	Survivors of gynecologic malignancies: impact of treatment on health and well-being. <i>Journal of Cancer Survivorship</i> , <b>2016</b> , 10, 261-70	5.1	37
116	What Is the Real Rate of Surgical Site Infection?. <i>Journal of Oncology Practice</i> , <b>2016</b> , 12, e878-e883	3.1	12
115	How low should we go: A systematic review and meta-analysis of the impact of restrictive red blood cell transfusion strategies in oncology. <i>Cancer Treatment Reviews</i> , <b>2016</b> , 46, 1-8	14.4	29
114	Targeting those with decreased meaning and peace: a supportive care opportunity. <i>Supportive Care in Cancer</i> , <b>2015</b> , 23, 2025-32	3.9	15
113	Impact of Age and Primary Disease Site on Outcome in Women With Low-Grade Serous Carcinoma of the Ovary or Peritoneum: Results of a Large Single-Institution Registry of a Rare Tumor. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 2675-82	2.2	55
112	Feeling powerless: Locus of control as a potential target for supportive care interventions to increase quality of life and decrease anxiety in ovarian cancer patients. <i>Gynecologic Oncology</i> , <b>2015</b> , 138, 388-93	4.9	20

111	Retrospective review of symptoms and palliative care interventions in women with advanced cervical cancer. <i>Gynecologic Oncology</i> , <b>2015</b> , 139, 553-8	4.9	24
110	Effects of music relaxation video on pain and anxiety for women with gynaecological cancer receiving intracavitary brachytherapy: a randomised controlled trial. <i>Journal of Research in Nursing</i> , <b>2015</b> , 20, 129-144	0.9	4
109	Perioperative blood transfusion in gynecologic oncology surgery: analysis of the National Surgical Quality Improvement Program Database. <i>Gynecologic Oncology</i> , <b>2015</b> , 136, 65-70	4.9	40
108	Gynecologic Cancer Survivorship Management <b>2015</b> , 125-143		
107	Diagnosis and Management of Stage II Endometrial Cancer <b>2015</b> , 293-305		
106	Missed opportunities: Patterns of medical care and hospice utilization among ovarian cancer patients. <i>Gynecologic Oncology</i> , <b>2014</b> , 135, 244-8	4.9	24
105	A phase II study of ramucirumab (IMC-1121B) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 478-85	4.9	22
104	Overall survival after pelvic exenteration for gynecologic malignancy. <i>Gynecologic Oncology</i> , <b>2014</b> , 134, 546-51	4.9	59
103	Risk perception, worry, and test acceptance in average-risk women who undergo ovarian cancer screening. <i>American Journal of Obstetrics and Gynecology</i> , <b>2014</b> , 210, 257.e1-6	6.4	7
102	Use of social media to conduct a cross-sectional epidemiologic and quality of life survey of patients with neuroendocrine carcinoma of the cervix: a feasibility study. <i>Gynecologic Oncology</i> , <b>2014</b> , 132, 149-53	4.9	27
101	Lifestyle modification in cervical cancer survivors: an ongoing need. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 570-5	3.5	7
100	Does death anxiety affect end-of-life care discussions?. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 1521-6	3.5	31
99	Patient preferences for side effects associated with cervical cancer treatment. <i>International Journal of Gynecological Cancer</i> , <b>2014</b> , 24, 1077-84	3.5	8
98	Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. <i>Gynecologic Oncology</i> , <b>2013</b> , 130, 323-8	4.9	45
97	Capturing the patient's experience: using qualitative methods to develop a measure of patient-reported symptom burden: an example from ovarian cancer. <i>Journal of Pain and Symptom Management</i> , <b>2013</b> , 46, 837-45	4.8	18
96	A prospective phase II study of chemoradiation followed by adjuvant chemotherapy for FIGO stage I-III A (1988) uterine papillary serous carcinoma of the endometrium. <i>Gynecologic Oncology</i> , <b>2013</b> , 129, 304-9	4.9	19
95	Prospective study of symptom assessment among patients with cervical cancer during concurrent chemoradiotherapy with weekly cisplatin or every-3-week cisplatin and 5-fluorouracil. <i>International Journal of Gynecological Cancer</i> , <b>2013</b> , 23, 1520-7	3.5	3
94	Social-cognitive theory predictors of exercise behavior in endometrial cancer survivors. <i>Health Psychology</i> , <b>2013</b> , 32, 1137-48	5	38

93	Hormonal therapy for recurrent low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , <b>2012</b> , 125, 661-6	4.9	117
92	Reclassification of serous ovarian carcinoma by a 2-tier system: a Gynecologic Oncology Group Study. <i>Cancer</i> , <b>2012</b> , 118, 3087-94	6.4	118
91	Unverifiable accomplishments and publications on applications for gynecologic oncology fellowships. <i>Obstetrics and Gynecology</i> , <b>2012</b> , 119, 504-8	4.9	5
90	Willingness of pregnant women to vaccinate themselves and their newborns with the HPV vaccine. <i>Vaccine</i> , <b>2011</b> , 29, 4618-22	4.1	3
89	Is low-grade serous ovarian cancer part of the tumor spectrum of hereditary breast and ovarian cancer?. <i>Gynecologic Oncology</i> , <b>2011</b> , 120, 229-32	4.9	15
88	Improved survival in non-Ashkenazi Jewish ovarian cancer patients with BRCA1 and BRCA2 gene mutations. <i>Gynecologic Oncology</i> , <b>2011</b> , 121, 358-63	4.9	28
87	Low-grade serous primary peritoneal carcinoma. <i>Gynecologic Oncology</i> , <b>2011</b> , 121, 482-6	4.9	36
86	Ethics consultation on a gynecologic oncology service: an opportunity for physician education. <i>Journal of Cancer Education</i> , <b>2011</b> , 26, 183-7	1.8	4
85	Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. <i>Cancer</i> , <b>2011</b> , 117, 2659-67	6.4	21
84	Clinicodemographic factors influencing outcomes in patients with low-grade serous ovarian carcinoma. <i>Cancer</i> , <b>2011</b> , 117, 3741-9	6.4	22
83	A phase I trial of liposomal doxorubicin, bevacizumab, and temsirolimus in patients with advanced gynecologic and breast malignancies. <i>Clinical Cancer Research</i> , <b>2011</b> , 17, 6840-6	12.9	42
82	Cancer-associated retinopathy in neuroendocrine carcinoma of the fallopian tube. <i>Journal of Neuro-Ophthalmology</i> , <b>2010</b> , 30, 252-4	2.6	11
81	Phase I clinical trials in 85 patients with gynecologic cancer: the M. D. Anderson Cancer Center experience. <i>Gynecologic Oncology</i> , <b>2010</b> , 117, 467-72	4.9	14
80	Human papillomavirus vaccine acceptability: is multimedia education ready for prime time?. <i>Gynecologic Oncology</i> , <b>2010</b> , 118, 101-2	4.9	2
79	Symptom research in gynecologic oncology: a review of available measurement tools. <i>Gynecologic Oncology</i> , <b>2010</b> , 119, 384-9	4.9	17
78	Pelvic fractures after radiotherapy for cervical cancer: implications for survivors. <i>Cancer</i> , <b>2010</b> , 116, 625-30	8.1	87
77	Caring for cancer patients in the future: a perfect storm on the horizon?. <i>Oncology</i> , <b>2010</b> , 24, 1351-2	1.8	1
76	Concurrent chemoradiation in the routine management of patients with cervical cancer: does marital status matter?. <i>International Journal of Gynecological Cancer</i> , <b>2009</b> , 19, 1107-12	3.5	3

75	Associations with worry about dying and hopelessness in ambulatory ovarian cancer patients. <i>Palliative and Supportive Care</i> , <b>2009</b> , 7, 299-306	2.5	35
74	Surgical education and training program development for gynecologic oncology: American perspective. <i>Gynecologic Oncology</i> , <b>2009</b> , 114, S47-51	4.9	15
73	Uterine smooth muscle tumor of uncertain malignant potential: a retrospective analysis. <i>Gynecologic Oncology</i> , <b>2009</b> , 113, 324-6	4.9	108
72	Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. <i>Gynecologic Oncology</i> , <b>2009</b> , 114, 48-52	4.9	176
71	Survival after intestinal perforation: can it be predicted?. <i>Gynecologic Oncology</i> , <b>2009</b> , 115, 349-53	4.9	3
70	Physical activity and obesity in endometrial cancer survivors: associations with pain, fatigue, and physical functioning. <i>American Journal of Obstetrics and Gynecology</i> , <b>2009</b> , 200, 288.e1-8	6.4	64
69	Perception of screening and risk reduction surgeries in patients tested for a BRCA deleterious mutation. <i>Cancer</i> , <b>2009</b> , 115, 1598-604	6.4	29
68	Alveolar soft part sarcoma of the cervix: case report and literature review. <i>Archives of Gynecology and Obstetrics</i> , <b>2009</b> , 279, 263-5	2.5	7
67	Dosing chemotherapy in obese patients: actual versus assigned body surface area (BSA). <i>Cancer Treatment Reviews</i> , <b>2009</b> , 35, 69-78	14.4	74
66	Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. <i>Gynecologic Oncology</i> , <b>2008</b> , 108, 510-4	4.9	153
65	Evaluation of pemetrexed (Alimta, LY231514) as second line chemotherapy in persistent or recurrent carcinoma of the cervix: a phase II study of the Gynecologic Oncology Group. <i>Gynecologic Oncology</i> , <b>2008</b> , 110, 65-70	4.9	40
64	Laparoscopy training in gynecologic oncology fellowship programs. <i>Gynecologic Oncology</i> , <b>2008</b> , 111, 197-201	4.9	14
63	Coordinated prophylactic surgical management for women with hereditary breast-ovarian cancer syndrome. <i>BMC Cancer</i> , <b>2008</b> , 8, 101	4.8	19
62	Carcinoma of the lower uterine segment: a newly described association with Lynch syndrome. <i>Journal of Clinical Oncology</i> , <b>2008</b> , 26, 5965-71	2.2	156
61	Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 5437-46	12.9	58
60	Comparison of treatment tolerance and outcomes in patients with cervical cancer treated with concurrent chemoradiotherapy in a prospective randomized trial or with standard treatment. <i>International Journal of Radiation Oncology Biology Physics</i> , <b>2008</b> , 70, 118-25	4	37
59	Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. <i>Gynecologic Oncology</i> , <b>2007</b> , 104, 100-3	4.9	102
58	Primary adenocarcinoma of the vagina not associated with diethylstilbestrol (DES) exposure. <i>Gynecologic Oncology</i> , <b>2007</b> , 105, 470-4	4.9	54

57	Comparison of the clinical behavior of newly diagnosed stages II-IV low-grade serous carcinoma of the ovary with that of serous ovarian tumors of low malignant potential that recur as low-grade serous carcinoma. <i>Gynecologic Oncology</i> , <b>2007</b> , 105, 625-9	4.9	61
56	Successful catheter-directed venous thrombolysis in phlegmasia cerulea dolens. <i>Gynecologic Oncology</i> , <b>2007</b> , 107, 140-2	4.9	22
55	Quality of life for patients with epithelial ovarian cancer. <i>Nature Clinical Practice Oncology</i> , <b>2007</b> , 4, 18-29		45
54	Overexpression of the centrosomal protein Aurora-A kinase is associated with poor prognosis in epithelial ovarian cancer patients. <i>Clinical Cancer Research</i> , <b>2007</b> , 13, 4098-104	12.9	119
53	Significantly greater expression of ER, PR, and ECAD in advanced-stage low-grade ovarian serous carcinoma as revealed by immunohistochemical analysis. <i>International Journal of Gynecological Pathology</i> , <b>2007</b> , 26, 404-9	3.2	94
52	Tubo-Ovarian Abscess Following Small Bowel Perforation Caused by Entamoeba histolytica. <i>Journal of Pelvic Medicine &amp; Surgery</i> , <b>2007</b> , 13, 27-28		1
51	Medical and Psychosocial Issues in Gynecologic Cancer Survivors <b>2007</b> , 114-121		
50	A phase II study of irifolven in women with recurrent and heavily pretreated ovarian cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 101, 55-61	4.9	26
49	Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers. <i>Gynecologic Oncology</i> , <b>2006</b> , 101, 126-31	4.9	89
48	A phase II trial of oral capecitabine in patients with platinum--and taxane--refractory ovarian, fallopian tube, or peritoneal cancer. <i>Gynecologic Oncology</i> , <b>2006</b> , 102, 468-74	4.9	9
47	Are women ready for the HPV vaccine?. <i>Gynecologic Oncology</i> , <b>2006</b> , 103, 151-4	4.9	80
46	Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. <i>Cancer</i> , <b>2006</b> , 106, 2452-8	6.4	123
45	Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. <i>Obstetrics and Gynecology</i> , <b>2006</b> , 108, 361-8	4.9	198
44	Prophylactic bilateral salpingo-oophorectomy compared with surveillance in women with BRCA mutations. <i>Obstetrics and Gynecology</i> , <b>2006</b> , 108, 515-20	4.9	52
43	Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 172-80	9.7	307
42	Sexual function after gynecologic cancer. <i>Obstetrics and Gynecology Clinics of North America</i> , <b>2006</b> , 33, 621-30, ix	3.3	48
41	Association of low-grade endometrioid carcinoma of the uterus and ovary with undifferentiated carcinoma: a new type of dedifferentiated carcinoma?. <i>International Journal of Gynecological Pathology</i> , <b>2006</b> , 25, 52-8	3.2	182
40	Quality of Life and Sexual Functioning <b>2006</b> , 261-278		

39	Medical and Psychosocial Issues in Gynecologic Cancer Survivors <b>2006</b> , 1838-1845		
38	Uterine Sarcomas <b>2006</b> , 125-147		4
37	A uterine leiomyosarcoma that became positive for HMB45 in the metastasis. <i>Annals of Diagnostic Pathology</i> , <b>2005</b> , 9, 43-5	2.2	34
36	American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7703-20	2.2	1404
35	Undifferentiated carcinoma of the endometrium. <i>American Journal of Surgical Pathology</i> , <b>2005</b> , 29, 1316-21	2.2	160
34	What's new in gynecology and obstetrics. <i>Journal of the American College of Surgeons</i> , <b>2005</b> , 201, 265-74	4.4	1
33	Phase II trial of capecitabine in recurrent squamous cell carcinoma of the cervix. <i>Gynecologic Oncology</i> , <b>2005</b> , 97, 840-4	4.9	14
32	Quality of life in cervix cancer survivors--what matters the most in the long-term?. <i>Gynecologic Oncology</i> , <b>2005</b> , 97, 307-9	4.9	10
31	Rankings and symptom assessments of side effects from chemotherapy: insights from experienced patients with ovarian cancer. <i>Supportive Care in Cancer</i> , <b>2005</b> , 13, 219-27	3.9	225
30	Quality of life and gynecologic malignancies. <i>Current Oncology Reports</i> , <b>2005</b> , 7, 459-65	6.3	10
29	Quality of life and sexual functioning in cervical cancer survivors. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 7428-36	2.2	306
28	Predictors of sexual functioning in ovarian cancer patients. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 881-9	2.2	156
27	An assessment of the utilization of complementary and alternative medication in women with gynecologic or breast malignancies. <i>Journal of Clinical Oncology</i> , <b>2004</b> , 22, 671-7	2.2	146
26	Vacuum-assisted closure in the treatment of gynecologic oncology wound failures. <i>Gynecologic Oncology</i> , <b>2004</b> , 92, 586-91	4.9	42
25	A phase I study of Adp53 (INGN 201; ADVEXIN) for patients with platinum- and paclitaxel-resistant epithelial ovarian cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 94, 442-8	4.9	58
24	Laparoscopic training and practice in gynecologic oncology among Society of Gynecologic Oncologists members and fellows-in-training. <i>Gynecologic Oncology</i> , <b>2004</b> , 94, 746-53	4.9	57
23	Hormonal therapy for the management of grade 1 endometrial adenocarcinoma: a literature review. <i>Gynecologic Oncology</i> , <b>2004</b> , 95, 133-8	4.9	262
22	Predictors of final histology in patients with endometrial cancer. <i>Gynecologic Oncology</i> , <b>2004</b> , 95, 463-8	4.9	104



21	Frozen section analyses as predictors of lymphatic spread in patients with early-stage uterine cancer. <i>Journal of the American College of Surgeons</i> , <b>2004</b> , 199, 388-93	4.4	115
20	Evaluation of patient chemotherapy education in a gynecology oncology center. <i>Supportive Care in Cancer</i> , <b>2004</b> , 12, 577-83	3.9	6
19	Does tamoxifen use affect prognosis in breast cancer patients who develop endometrial cancer?. <i>Obstetrics and Gynecology</i> , <b>2004</b> , 104, 255-60	4.9	17
18	Grading ovarian serous carcinoma using a two-tier system. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 496-504	6.7	489
17	Uterine epithelioid leiomyosarcomas with clear cells: reactivity with HMB-45 and the concept of PEComa. <i>American Journal of Surgical Pathology</i> , <b>2004</b> , 28, 244-9	6.7	127
16	Quality of Life in the Gynecologic Cancer Patient <b>2004</b> , 785-794		2
15	Mentorship and productivity among gynecologic oncology fellows. <i>Journal of Cancer Education</i> , <b>2003</b> , 18, 15-9	1.8	28
14	beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma. <i>Gynecologic Oncology</i> , <b>2003</b> , 88, 363-8	4.9	42
13	Sarcomatoid carcinoma of the cervix. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 23-8	4.9	29
12	Groin recurrence in patients with vulvar cancer with negative nodes on superficial inguinal lymphadenectomy. <i>Gynecologic Oncology</i> , <b>2003</b> , 90, 625-8	4.9	65
11	Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium. <i>Cancer</i> , <b>2003</b> , 98, 758-64	6.4	97
10	Cervical cancer. <i>Cancer</i> , <b>2003</b> , 98, 2009-14	6.4	37
9	Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer. <i>Journal of Clinical Oncology</i> , <b>2003</b> , 21, 291-7	2.2	87
8	E-motions: email for written emotional expression. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3352-5	2.2	7
7	Endovascular management of ureteral-iliac artery fistulae with Wallgraft endoprosthesis. <i>Gynecologic Oncology</i> , <b>2002</b> , 85, 212-7	4.9	26
6	Trends among gynecologic oncology inpatient deaths: is end-of-life care improving?. <i>Gynecologic Oncology</i> , <b>2002</b> , 85, 356-61	4.9	21
5	Patient preferences regarding side effects of chemotherapy for ovarian cancer: do they change over time?. <i>Gynecologic Oncology</i> , <b>2002</b> , 87, 118-28	4.9	58
4	Correlation of smoking history and other patient characteristics with major complications of pelvic radiation therapy for cervical cancer. <i>Journal of Clinical Oncology</i> , <b>2002</b> , 20, 3651-7	2.2	147

3	Response and survival in patients with progressive or recurrent serous ovarian tumors of low malignant potential. <i>Obstetrics and Gynecology</i> , <b>2002</b> , 99, 3-10	4.9	118
2	Growth suppression of human ovarian cancer cell lines by the introduction of a p16 gene via a recombinant adenovirus. <i>Gynecologic Oncology</i> , <b>1999</b> , 73, 27-34	4.9	30
1	Cost-effectiveness analysis of diagnosis and management of cervical squamous intraepithelial lesions. <i>Obstetrics and Gynecology</i> , <b>1998</b> , 91, 270-7	4.9	42